LONDON (Reuters) – An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday.
GW, which is developing the drug Sativex for pain in collaboration with Japan’s Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo.
LONDON, Jan 7 (Reuters) – Novartis is diving
deeper into the world of gene-based medicine by signing deals
with two U.S. biotech companies, giving it access to a powerful
new genome editing technology.
The tie-ups with unlisted Intellia Therapeutics and Caribou
Biosciences show the Swiss drugmaker’s confidence in the
potential of so-called CRISPR technology, both for making new
medicines and as a research tool.
LONDON (Reuters) – Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark’s Bavarian Nordic, making it the third such shot to enter human testing.
The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year.